• Cytos Biotechnology Ltd., of Zurich, Switzerland, said it completed a CHF23.75 million (US$25.2 million) equity investment. The financing is part of a planned CHF37 million debt and equity deal to be provided by an international syndicate of investors, including venBio, Abingworth, Aisling Capital and Amgen. Cytos intends to use the proceeds primarily to conduct a Phase IIb study of CYT003 in allergic asthma. Read More

LONDON – Medgenics Inc. got the go-ahead for the first U.S. trial of its autologous biopump technology, with the FDA approving a Phase IIb trial of Epodure, an implant of a patient's own skin that has been engineered to manufacture erythropoietin (EPO). Read More

Shares in Diamyd Medical AB edged up more than 6 percent Tuesday on news that the company completed recruitment in a 32-patient, Phase II trial of its gene therapy treatment for chronic cancer pain, NP2 Enkephalin. Read More

LONDON – Particle engineering specialist Prosonix Ltd. has raised a further £5.7 million (US$9 million) in a second closing of Series B funding, taking the total for the round to £17.1 million. Read More

LONDON – Whole-genome analysis of 21 individual breast cancers has yielded a glimpse of the enormous number, type and extent of mutations present in breast tumors. Read More

LONDON – The timing could not have been better. The international stem cell community getting together in London was able to applaud the breakthrough signified by Health Canada's approval of Prochymal, Osiris Therapeutics Inc.'s allogeneic stem cell treatment for graft-vs.-host disease, and rejoice in the knowledge that there is light at the end of the regulatory tunnel. Read More